ProAxsis

Executive Summary

ProAxsis is a commercial-stage respiratory diagnostics company headquartered in Belfast, Northern Ireland, specializing in the measurement of active protease activity—a key biomarker in chronic respiratory diseases such as COPD, cystic fibrosis, and asthma. The company’s proprietary ProteaseTag® technology enables highly sensitive, specific detection of active proteases in biological samples. ProAxsis has developed a suite of assays for research use, clinical trial applications, and point-of-care testing, positioning itself as a critical enabler of precision medicine in respiratory care. With a portfolio that includes both laboratory-based and near-patient formats, the company addresses a significant unmet need for real-time monitoring of disease activity and treatment response. ProAxsis operates in a growing market driven by rising prevalence of chronic respiratory conditions and increasing adoption of biomarker-guided therapies. The company’s differentiation lies in its ability to directly measure active protease levels, as opposed to total protein or genetic markers, which offers higher clinical relevance. As it scales commercialization, ProAxsis is well-positioned to capture value from pharmaceutical partnerships, clinical trial services, and direct sales of diagnostic kits. The company’s technology has the potential to become the standard of care for protease activity monitoring, with multiple opportunities for expansion into other inflammatory and fibrotic diseases. Continued investment in regulatory approvals and clinical evidence will be key to unlocking broader market access.

Upcoming Catalysts (preview)

• Q3 2026CE marking or FDA clearance for point-of-care ProteaseTag® assay50% success
• Q2 2026Major pharmaceutical partnership for clinical trial biomarker testing60% success
• Q4 2026Publication of pivotal clinical validation study in a peer-reviewed journal70% success